Financial
News release
TopTOKYO, JAPAN - March 31, 2025 - Terumo Corporation (TSE: 4543) today announced the establishment of “D-TECT” (Discovery and TEchnology Center of Terumo), a new R&D center in the United States. Strategically located in Aliso Viejo, California, the new center will facilitate collaboration with local medical institutions, academia and startups to reinforce Terumo’s global Corporate R&D capabilities, while supporting R&D functions of the Group companies across the country by utilizing its own core technology.
Photo of the D-TECT office
Terumo's Corporate R&D is responsible for creating new projects and innovative technologies that will drive the future growth of the entire Terumo Group, with a focus on mid to long-term projects for Terumo’s business units and totally new area for Terumo. Primarily driven by the research teams based in Japan, the Corporate R&D has also been developing the Group's core technologies by conducting field-based research and working with various stakeholders, including medical professionals.
By establishing D-TECT as a satellite base of the Corporate R&D, Terumo will further accelerate its research and development activities in the U.S., the largest market for medical devices. The new center will also play a key role in transferring the company's core technologies, such as coating technology, metal materials and manufacturing technology, and evaluation technology, to other Group companies in the United States. In addition, it will explore new technologies emerging from local startups and academia, aiming to further deepen Terumo's technological capabilities.
D-TECT consists of two teams: one team is in charge of driving product development projects, and the other team supports the R&D or manufacturing of the Group companies by leveraging technological expertise in the fields of coatings, metal manufacturing processing, and others. The new center has been established with a staff of about 10 researchers, including those seconded from the Corporate R&D in Japan as well as locally hired researchers. The company plans to gradually expand the functionalities and scale of the center, with the goal of having a team of 30 researchers within five years.
"I am thrilled with the establishment of D-TECT, our latest initiative to expand Terumo's Corporate R&D operations globally and to strengthen our ability to innovate,” said Dr. Shinji Omori, Chief Technology Officer (CTO), Terumo Corporation. “I firmly believe that the new center will play a pivotal role in generating new technologies that will drive the next growth of the Terumo Group through close collaboration with various stakeholders in the U.S."
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.